Dulan Lokuwithana
Senior Healthcare News Editor at Seeking Alpha
🧡 Senior healthcare news editor @seekingalpha – connecting the dots between healthcare and Wall Street; Ex-Moody's, 🎓Edu.: CFA (US), CIMA (UK) & USJP 🇱🇰
Articles
-
3 days ago |
seekingalpha.com | Dulan Lokuwithana
mphillips007Neogen Corporation (NASDAQ:NEOG) lost ~14% in the morning hours on Wednesday after the food safety player updated its Q4 fiscal 2025 outlook in conjunction with a presentation at the ongoing William Blair Growth Stock Conference in Chicago, Illinois. While the
-
3 days ago |
seekingalpha.com | Dulan Lokuwithana
bin kontan/iStock via Getty ImagesFollowing a ~7% rise in the previous session, AnaptysBio (NASDAQ:ANAB) extended gains in the premarket on Wednesday after the biotech announced additional data from a mid-stage trial for its lead asset rosnilimab against the autoimmune disorder rheumatoid arthritis. Citing 12-week data
-
3 days ago |
seekingalpha.com | Dulan Lokuwithana
-
3 days ago |
seekingalpha.com | Dulan Lokuwithana
Maddie Meyer/Getty Images NewsModerna (NASDAQ:MRNA) has agreed to conduct another placebo-controlled clinical trial for its newly approved next-gen COVID-19 vaccine, Health and Human Services Secretary Robert F. Kennedy Jr. has said. Late last week, the FDA approved the messenger RNA-based shot branded as mNEXSPIKE
-
3 days ago |
seekingalpha.com | Dulan Lokuwithana
Richard Drury Vigil Neuroscience (NASDAQ:VIGL) announced on Wednesday that a mid-stage trial for its lead candidate, iluzanebart, didn’t succeed in patients with a rare neurological disease called adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP). The Watertown, Massachusetts-based biotech, which recently agreed to
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →Coverage map
X (formerly Twitter)
- Followers
- 287
- Tweets
- 4K
- DMs Open
- No
RT @FoodFun70336745: $VKTX Pfizer hints at acquisitions to boost obesity pipeline after trial setback Going forward, we are committed to b…
RT @NatRevDrugDisc: GLP-1-based therapies for diabetes, obesity and beyond https://t.co/JmGtGmwUTv This new review by @DanielJDrucker prof…
RT @BowTiedBiotech: 🏗️ $165B+ Committed to U.S. Pharma Manufacturing Biopharma is building at full tilt 👇🏼 🔸 $55B - $JNJ (4 yrs) 🔸 $50B -…